Editor's note channel feed

I’m head­ed to Lon­don soon for #EU­BIO22. Care to join me?

3 years ago

Who are the women blaz­ing trails in bio­phar­ma R&D? Nom­i­nate them for End­points' 2022 spe­cial re­port

3 years ago

End­points ed­i­tors se­lect the top trends of 2022: M&A looks hot as IPOs wane, it's time to see some hard da­ta on AI and can ac­cel­er­at­ed ap­proval re­main in­tact?

3 years ago
Special

Who are the women su­per­charg­ing bio­phar­ma R&D? Nom­i­nate them for this year's spe­cial re­port

4 years ago

End­points News wants to know: Is your com­pa­ny man­dat­ing Covid-19 vac­cines?

4 years ago
Pharma

Fol­low biotechs go­ing pub­lic with the End­points News IPO Track­er

4 years ago

Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

4 years ago

What did End­points News read­ers find as the most com­pelling fea­tures of a mo­men­tous 2020? Here are the top 10

4 years ago

Our 3rd an­nu­al UK bio­phar­ma event tops this week — on Zoom — with José Basel­ga, top biotech CEOs and a look at the glob­al fi­nan­cial scene

5 years ago

Who are the women blaz­ing trails in bio­phar­ma R&D and lead­ing the fight against Covid-19? Nom­i­nate them for End­points' spe­cial re­port

5 years ago
People

Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

5 years ago

The End­points 100: No­var­tis gets 'poor' grade on da­ta scan­dal, Ned Sharp­less is­n't a 'wow' and that Cana­da drug im­por­ta­tion plan is a non­starter

6 years ago

That feel­ing you get when you hit the fin­ish line, and then set new goals

6 years ago
Bioregnum
Opinion

Who are the women blaz­ing trails in bio­phar­ma R&D? Nom­i­nate them for End­points' spe­cial re­port

6 years ago

Come join me dur­ing my round-the-world biotech ad­ven­ture in Oc­to­ber, with events in Lon­don and Shang­hai — plus

7 years ago

The 10 most pop­u­lar sto­ries in End­points News — so far in 2017

8 years ago

Let the joust­ing be­gin: Which top bio­phar­ma com­pa­nies are look­ing to make a splash at ASH?

8 years ago
R&D

We've tak­en a big step for­ward at End­points News — and with your help, we'll make more strides

8 years ago

The busi­ness mod­el of End­points News — and why you should sub­scribe

8 years ago

End­points In­sid­er: The world’s old­est new biotech pub ends its 12th month on a roll

8 years ago

Cheers! End­points News turns 1 to­day — and we're un­wrap­ping in­fo on a new sub­scrip­tion plan

8 years ago

The 10 most pop­u­lar re­ports in End­points News — so far

9 years ago

What is End­points?

9 years ago
First page Previous page 12
A service from the Financial Times